

Microba and Genova Diagnostics Partnership Commences in United States

- First microbiome tests in recently signed partnership with Genova Diagnostics will be made available to healthcare practitioners in the United States from today
- Together, Microba and Genova have established a CLIA/CAP metagenomic laboratory in North Carolina enabling gut microbiome tests, using Microba's Analysis Platform, to be deployed with rapid turnaround times
- Genova Diagnostics is a leading gastrointestinal pathology provider in North America that serves more than 10,000 primary care physicians, specialists and other healthcare providers

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a precision microbiome company, is pleased to announce that the first of Genova Diagnostics' ("Genova") gut microbiome tests, powered by Microba's Analysis Platform, will be made available to healthcare practitioners from today in the United States.

The test will provide Genova's healthcare practitioner customers with the most complete view of their patients' gut microbiome available on market, to enable more effective patient management.

Together, Microba and Genova have established a CLIA/CAP accredited metagenomic laboratory in North Carolina. This facility will enable the processing and sequencing of Genova customer samples in the US to ensure rapid turnaround times.

Genova's CEO Jeff Ledford said, "We pride ourselves in bringing the latest testing solutions to practitioners and their patients. Genova has been pioneering testing solutions for personalised and preventative care since 1986. Our partnership with Microba has enabled us to develop an advanced microbiome test offering, which has been a key gap for practitioners supporting their patients with chronic conditions."

Microba's CEO Dr Luke Reid said, "Scientifically and medically aligned partners such as Genova are important to make our technology rapidly available to practitioners and their patients globally to improve health care. We are pleased to see our testing technology coming to practitioners in North America with a true pioneer and leader in the field of gastrointestinal testing."

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Genova Diagnostics

Genova Diagnostics provides comprehensive and innovative clinical laboratory services for the prevention, diagnosis and treatment of complex chronic disease. Headquartered in Asheville, N.C., Genova Diagnostics is a global clinical laboratory, pioneering a systems approach that supports healthcare providers in the personalized treatment and prevention of chronic disease.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.